These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 22002453)

  • 1. Cost evaluation of evidence-based treatments.
    Sindelar JL; Ball SA
    Addict Sci Clin Pract; 2010 Dec; 5(2):44-51. PubMed ID: 22002453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic evaluation of drug abuse treatment programs: methodology and findings.
    French MT
    Am J Drug Alcohol Abuse; 1995 Feb; 21(1):111-35. PubMed ID: 7762538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response: thoughtfulness required.
    Brigham G; Jackson R; Wood J
    Addict Sci Clin Pract; 2010 Dec; 5(2):51-3. PubMed ID: 22002454
    [No Abstract]   [Full Text] [Related]  

  • 4. Estimating the economic cost of substance abuse treatment.
    French MT; McGeary KA
    Health Econ; 1997; 6(5):539-44. PubMed ID: 9353658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How to develop cost-conscious guidelines.
    Eccles M; Mason J
    Health Technol Assess; 2001; 5(16):1-69. PubMed ID: 11427188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incorporating considerations of cost-effectiveness, affordability, and resource implications in guideline development: article 6 in Integrating and coordinating efforts in COPD guideline development. An official ATS/ERS workshop report.
    Hill SR; Olson LG; Falck-Ytter Y; Cruz AA; Atkins D; Baumann M; Jaeschke R; Woitalla T; Schünemann HJ;
    Proc Am Thorac Soc; 2012 Dec; 9(5):251-5. PubMed ID: 23256167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence-based treatment: why, what, where, when, and how?
    Miller WR; Zweben J; Johnson WR
    J Subst Abuse Treat; 2005 Dec; 29(4):267-76. PubMed ID: 16311179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of family-based substance abuse treatment.
    Morgan TB; Crane DR
    J Marital Fam Ther; 2010 Oct; 36(4):486-98. PubMed ID: 21039660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Substance abuse treatment, what do we know? An economist's perspective.
    Machado MP
    Eur J Health Econ; 2005 Mar; 6(1):53-64. PubMed ID: 15703912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Economic evaluation in health: applications in infectious diseases].
    Vanni T; Luz PM; Ribeiro RA; Novaes HM; Polanczyk CA
    Cad Saude Publica; 2009 Dec; 25(12):2543-52. PubMed ID: 20191146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting evidence-based treatment sustainment: results from a longitudinal study of the Adolescent-Community Reinforcement Approach.
    Hunter SB; Han B; Slaughter ME; Godley SH; Garner BR
    Implement Sci; 2017 Jun; 12(1):75. PubMed ID: 28610574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using the DATCAP and ASI to estimate the costs and benefits of residential addiction treatment in the State of Washington.
    French MT; Salomé HJ; Carney M
    Soc Sci Med; 2002 Dec; 55(12):2267-82. PubMed ID: 12409139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic costs of drug abuse: financial, cost of illness, and services.
    Cartwright WS
    J Subst Abuse Treat; 2008 Mar; 34(2):224-33. PubMed ID: 17596904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Research on the diffusion of evidence-based treatments within substance abuse treatment: a systematic review.
    Garner BR
    J Subst Abuse Treat; 2009 Jun; 36(4):376-99. PubMed ID: 19008068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefit-cost analysis of addiction treatment: methodological guidelines and empirical application using the DATCAP and ASI.
    French MT; Salomé HJ; Sindelar JL; McLellan AT
    Health Serv Res; 2002 Apr; 37(2):433-55. PubMed ID: 12036002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of a mixed-gender aftercare program for substance abuse: decomposing measured and unmeasured gender differences.
    Yeom HS; Shepard DS
    J Ment Health Policy Econ; 2007 Dec; 10(4):207-19. PubMed ID: 18166831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opportunity costs and uncertainty in the economic evaluation of health care interventions.
    Sendi P; Gafni A; Birch S
    Health Econ; 2002 Jan; 11(1):23-31. PubMed ID: 11788979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention validation and accounting platform: a framework for establishing accountability and performance measures of substance abuse prevention programs.
    Kim S; McLeod JH; Williams C; Hepler N
    J Drug Educ; 2000; 30(1):1-143. PubMed ID: 10893910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A cost-related approach for evaluating drug development programs.
    Yan EC; Chen L
    Stat Med; 2004 Sep; 23(18):2863-73. PubMed ID: 15344191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Consumer-Operated Service Programs: monetary and donated costs and cost-effectiveness.
    Yates BT; Mannix D; Freed MC; Campbell J; Johnsen M; Jones K; Blyler CR
    Psychiatr Rehabil J; 2011; 35(2):91-9. PubMed ID: 22020838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.